Effect of anti-tumor necrosis factor-α therapies on body mass index in patients with psoriasis

Pharmacological Research

Volumn 57, Issue 4, 2008, Pages 290-295

  Saraceno, Rosita ^a   Schipani, Caterina ^a   Mazzotta, Annamaria ^a   Esposito, Maria ^a   Di Renzo, Laura ^b,c   De Lorenzo, Antonino ^b,c   Chimenti, Sergio ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c INDiM   (Italy)

Author keywords

Biologics; Psoriasis; TNF ; Weight gain

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; SIDE EFFECT; WEIGHT GAIN;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BODY MASS INDEX; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 42749094559     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.02.006     Document Type: Article

References (26)

1. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 22 (2007) 866-873
2. Mc L. Psoriasis. Lancet 361 (2003) 1197-1204
3. Green L., Meyers O.L., Gordon W., and Briggs B. Arthritis in psoriasis. Ann Rheum Dis 40 (1981) 366-369
4. Sterry W., Strober B.E., Menter A, and On behalf of the International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications Report of an interdisciplinary conference and review. Br J Dermatol 157 (2007) 649-655
5. Bonta I.L., Ben-Efraim S., Mózes T., and Fieren M.W. Tumour necrosis factor in inflammation: relation to other mediators and to macrophage antitumour defence. Pharmacol Res 24 (1991) 115-130
6. Asadullah K., Sterry W., and Volk H.D. Analysis of cytokine expression dermatology. Arch Dermatol 138 (2002) 1189-1196
7. Li Y.P., Lecker S.H., Chen Y., Waddell I.D., Goldberg A.L., and Reid M.B. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17 (2003) 1048-1057
8. Gottlieb A.B. Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 4 (2005) 19-34
9. Gisondi P., Cotena C., Tessari G., and Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol 22 3 (2008) 341-344
10. Fredriksson T., and Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 157 (1978) 238-244
11. Warren R.B., and Griffiths C.E. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. Br J Dermatol 153 (2005) 869-873
12. Yanovski S.Z., and Yanovski J.A. Obesity. N Engl J Med 346 (2002) 591-602
13. Franchimont D., Roland S., Gustot T., Quertinmont E., Toubouti Y., Gervy M.C., et al. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab 90 (2005) 3510-3516
14. Briot K., Garnero P., Le Henanff A., Dougados M., and Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor {alpha} treatment. Ann Rheum Dis 64 (2005) 1137-1140
15. Marcora S.M., Chester K.R., Mittal G., Lemmey A.B., and Maddison P.J. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84 (2006) 1463-1472
16. Hohmann H.P., Remy R., Poschl B., and Van Loon A.P. Tumor necrosis factors-alpha and -beta bind to the same two types of tumor necrosis factor receptors and maximally activate the transcription factor NF-kappa B at low receptor occupancy and within minutes after receptor binding. J Biol Chem 265 (1990) 15183-15188
17. Bonifati C., and Ameglio F. Cytokines in psoriasis. Int J Dermatolol 38 (1999) 241-251
18. Di Renzo L., Bigioni M., Del Gobbo V., Premrov M.G., Barbini U., Di Lorenzo N., et al. Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight obese syndrome: relationship to body composition and IL-1 alpha and beta plasma levels. Pharmacol Res 55 (2007) 131-138 10.1016/j.phrs.2006.11.002
19. Argilés J.M., López-Soriano J., Busquets S., and López-Soriano F.J. Journey from cachexia to obesity by TNF. FASEB J 11 (1997) 743-745
20. Boehncke W.H., Prinz J., and Gottlieb A.B. Biologic therapies for psoriasis. A systematic review. J Rheumatol 33 (2006) 1447-1451
21. Henseler T., and Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 32 (1995) 982-986
22. Esposito M., Saraceno R., Giunta A., Maccarone M., and Chimenti S. An Italian study on psoriasis and depression. Dermatology 212 (2006) 123-127
23. Simon G.E., Ludman E.J., Linde J.A., Operskalski B.H., Ichikawa L., Rohde P., et al. Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry 30 (2008) 32-39
24. De groot M., Appelman M., Spuls P.I., de Rie M.A., and Bos J.D. Initial experience with routine administration of etanercept in psoriasis. Br J Dermatol 155 (2006) 808-814
25. Metsios G.S., Stavropoulos-Kalinoglou A., Douglas K.M., Koutedakis Y., Nevill A.M., Panoulas V.F., et al. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia. Rheumatology (Oxford) 46 12 (2007) 1824-1827
26. Metsios G.S., Stavropoulos-Kalinoglou A., Nevill A.M., Douglas K.M., Koutedakis Y., and Kitas G.D. Smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis. Ann Rheum Dis 67 (2008) 70-73